XML 52 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration and License Agreements - Additional Information (Detail) (USD $)
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Sep. 30, 2013
Les Laboratoires Servier [Member]
Sep. 30, 2012
Les Laboratoires Servier [Member]
Sep. 30, 2013
Les Laboratoires Servier [Member]
Sep. 30, 2012
Les Laboratoires Servier [Member]
Dec. 31, 2012
Les Laboratoires Servier [Member]
Sep. 30, 2013
Les Laboratoires Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2012
Les Laboratoires Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2013
Les Laboratoires Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2012
Les Laboratoires Servier [Member]
Second Right to Develop Collaboration [Member]
Dec. 31, 2012
Les Laboratoires Servier [Member]
Second Right to Develop Collaboration [Member]
Sep. 30, 2013
Gilead [Member]
Sep. 30, 2013
Gilead [Member]
Molecule
Program
Sep. 30, 2013
Boehringer [Member]
Sep. 30, 2012
Boehringer [Member]
Sep. 30, 2013
Boehringer [Member]
Molecule
Payments
Sep. 30, 2012
Boehringer [Member]
Dec. 31, 2012
Boehringer [Member]
Jan. 31, 2011
Boehringer [Member]
Series D-2 Convertible Preferred Stock [Member]
Oct. 31, 2010
Pfizer [Member]
Molecule
Sep. 30, 2013
Pfizer [Member]
Sep. 30, 2012
Pfizer [Member]
Sep. 30, 2013
Pfizer [Member]
Program
Sep. 30, 2012
Pfizer [Member]
Dec. 31, 2012
Pfizer [Member]
Sep. 30, 2013
Green Cross Corporation [Member]
Sep. 30, 2012
Green Cross Corporation [Member]
Sep. 30, 2013
Green Cross Corporation [Member]
Sep. 30, 2012
Green Cross Corporation [Member]
Dec. 31, 2012
Green Cross Corporation [Member]
Oct. 28, 2010
Eli Lilly [Member]
May 31, 2008
Eli Lilly [Member]
Sep. 30, 2013
Eli Lilly [Member]
Sep. 30, 2012
Eli Lilly [Member]
Sep. 30, 2013
Eli Lilly [Member]
Sep. 30, 2012
Eli Lilly [Member]
Dec. 31, 2012
Eli Lilly [Member]
License And Collaboration Agreements [Line Items]                                                                                  
Collaboration agreement date               November 2011         September 2012       January 2013     October 2010       October 2010               June 2010             October 2007    
Non-refundable upfront payment               $ 20,000,000         $ 20,000,000             $ 15,000,000       $ 5,000,000     $ 5,000,000         $ 1,000,000             $ 41,000,000    
License grant fees           30,000,000   30,000,000     65,000,000   65,000,000     7,500,000 7,500,000                                                
Clinical milestone payments               47,000,000         98,000,000                                                        
Regulatory milestone payments           140,000,000   140,000,000     300,000,000   300,000,000     355,000,000 355,000,000 89,000,000   89,000,000                                          
Sales milestone payments               208,000,000         630,000,000       500,000,000     83,000,000             195,000,000                            
Expected period of development               27 months         29 months       21 months                                                
Recognized revenue under agreement 20,111,173 15,532,680 42,015,994 50,283,510   12,300,000 2,300,000 18,900,000 6,800,000   2,200,000 0 6,500,000 0   2,200,000 5,900,000 2,300,000 2,500,000 6,900,000 9,300,000       900,000 1,200,000 3,200,000 4,000,000   25,000 25,000 75,000 75,000       190,833.0 9,500,000 673,927.0 30,100,000  
Milestone payment           10,000,000   10,000,000                       41,000,000   2,000,000             500,000             50,000,000          
Deferred revenue           3,100,000   3,100,000   10,000,000 11,600,000   11,600,000   18,000,000     10,300,000   10,300,000   14,000,000               675,000   675,000   750,000              
Deferred revenue included in current liabilities 21,298,318   21,298,318   24,123,176         9,100,000 8,600,000   8,600,000   8,600,000 4,400,000 4,400,000 5,000,000   5,000,000   5,000,000     58,000,000,000   58,000,000,000   1,300,000 100,000   100,000   100,000              
Deferred revenue included in long-term liabilities 8,812,342   8,812,342   19,956,343         900,000 3,000,000   3,000,000   9,400,000     5,300,000   5,300,000   9,000,000               575,000   575,000   650,000              
Clinical milestone payments under agreement                     5,000,000   5,000,000     200,000,000 200,000,000               17,000,000   17,000,000     4,500,000   4,500,000                  
Commercialization of molecules                                 4     10       2                                  
Molecules having exclusive worldwide rights                                 3                                                
Number of programs Company retains development and commercialization rights outside                                 1                                                
Additional license grant fees                               22,500,000 22,500,000                                                
Receivables 2,281,282   2,281,282   2,046,219                     1,100,000 1,100,000 246,375   246,375   355,568     501,794   501,794   896,285               244,542   244,542   558,516
Number of annual maintenance payments received                                       2                                          
Received including upfront, annual maintenance and milestone payment                                       39,000,000                                          
Preferred Stock purchased                                             $ 10,000,000                                    
Research obligation completion date                                       2015-09             2014-01                            
Period of agreement                                               3 years                                  
DART program                                                     1                            
Term of the agreement                                                               2020-06                  
Review of clinical data                                                                     1 year